查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048140

頭孢氨芐市場－全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局分類，2021-2031年

Cephalexin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球頭孢氨芐市場預計將從 2025 年的 3.8903 億美元成長到 2031 年的 5.1158 億美元，複合年成長率為 4.67%。

頭孢氨芐是一種第一代頭孢菌素類抗生素，廣泛用於治療呼吸道、皮膚和泌尿器官系統的細菌感染疾病。其市場成長主要得益於其作為學名藥已確立的臨床安全性和成本效益，確保了其在兒童和老年人群中的高處方量。此外，儘管新型抗菌藥物不斷湧現，但全球感染疾病的上升仍然推動了對這種重要抗生素的需求。然而，該市場面臨與供應鏈穩定性和生產一致性相關的重大挑戰，這常常導致產品短缺。學名藥生產利潤率低，加劇了這些物流難題，阻礙了擴大產能的投資。根據美國衛生系統藥劑師協會2025年4月報告，美國醫療保健產業發生了270起藥品短缺事件，凸顯了生產環節的脆弱性依然存在，威脅著頭孢氨芐等關鍵感染疾病物的供應。

市場概覽
預測期 2027-2031
市場規模：2025年 3.8903億美元
市場規模：2031年 5.1158億美元
複合年成長率：2026-2031年 4.67%
成長最快的細分市場 尿道感染
最大的市場 北美洲

市場促進因素

細菌性行為感染，尤其是呼吸道感染疾病的日益增多，從根本上支撐了頭孢氨芐的商業性需求。作為一種成熟的一線治療藥物，頭孢氨芐在對抗常見社區獲得性病原體方面仍然至關重要。流行病學趨勢顯示感染率不斷上升，進一步凸顯了這種依賴性。例如，美國疾病管制與預防中心 (CDC) 在 2024 年 7 月發布的報告《2021-2022 年美國抗菌素抗藥性威脅》中指出，院內感染比疫情前水準增加了 20%，這凸顯了隨時可獲得抗生素治療的必要性。同時，全球老化是重要的人口因素，由於老年人更容易感染尿道感染等疾病，頭孢氨芐的處方量也顯著增加。在這些老化社會中，持續獲得像頭孢氨芐這樣在療效和腎臟安全性之間取得良好平衡且副作用較少的藥物至關重要。根據聯合國經濟和社會事務部2024年10月發布的報告，到2024年，全球60歲及以上人口將達到12億，這將構成一個龐大的患者群體。這種人口結構變化帶來的壓力正在推動成熟非專利藥的消費。梯瓦製藥工業公司報告稱，其在美國的非專利業務在2024年第三季的銷售額成長了30%，這表明專利到期抗生素的需求勢頭強勁。

市場挑戰

全球頭孢氨芐市場面臨許多挑戰，包括供應鏈不穩定和生產差異，這些都直接阻礙了市場擴張。頭孢氨芐是一種利潤率較低的非專利抗生素，因此生產商缺乏投資擴大產能或升級老舊設施的經濟獎勵。這種經濟現實導致市場生態系統脆弱，生產往往集中在少數供應商手中，使得市場極易受到品管不善和原料短缺等因素的影響。這些物流瓶頸會導致巨大的收入損失和消費停滯，因為無法滿足持續的臨床需求。這些生產環節的脆弱性對抗感染疾病藥物領域的影響尤其嚴重，對關鍵治療藥物的供應造成了不成比例的影響。 2025年11月，歐洲醫院藥劑師協會報告稱，63%的受訪藥劑師表示，抗菌藥物是受供不應求影響最大的治療藥物類別。頻繁發生的此類斷貨迫使醫療系統發行現有庫存，從而有效地限制了市場的成長潛力，並造成了不穩定的商業環境，阻礙了該行業對頭孢氨芐生產的長期承諾。

市場趨勢

製造商正在加速從傳統的化學合成過程轉變為酵素法製程轉變，以生產頭孢氨芐原料藥（API）。這種「綠色化學」方法顯著減少了溶劑廢棄物，降低了能源消耗，並生產出高純度產品，符合全球永續性目標和嚴格的環境法規。透過採用酵素法平台，企業可以以更有效率的生物催化途徑取代複雜的化學工藝，從而顯著降低BETA-內醯胺類抗生素生產對環境的影響，同時最佳化運作效率。例如，Centrient Pharmaceuticals公司於2025年6月發布的ESG報告指出，與2024年的基準值相比，其範圍1和範圍2的溫室氣體排放將減少8%，這充分體現了製藥生產基礎設施現代化帶來的實際永續性效益。除了常見的人類應用外，市面上也出現了大量專為伴侶動物和牲畜設計的頭孢氨芐獸用製劑。這一新趨勢包括開發偏好極佳的咀嚼片和長效注射劑，旨在更有效地治療寵物細菌感染疾病，這一領域與典型的人類學名藥截然不同。這種專注於動物健康的策略源於越來越多的寵物及其飼主願意投資高階醫療，以治療皮膚病和尿道感染等疾病，從而為製造商創造了一個盈利的細分市場。根據碩騰公司（Zoetis）於2025年2月發布的2024年第四季及全年財報，2024年第四季其在美國的伴侶動物產品銷售額成長了7%，進一步印證了動物用藥品產業盈利的提升。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球頭孢氨芐市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 依用途分類（尿道感染、呼吸道感染疾病、中耳炎、骨骼感染疾病、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美頭孢氨芐市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲頭孢氨芐市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區頭孢氨芐市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：頭孢氨芐在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：頭孢氨芐在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球頭孢氨芐市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Lupin Limited
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Mylan NV
  • Alkem Laboratories Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28249

The Global Cephalexin Market is projected to expand from USD 389.03 Million in 2025 to USD 511.58 Million by 2031, reflecting a compound annual growth rate of 4.67%. Cephalexin, a first-generation cephalosporin antibiotic, is extensively used to treat bacterial infections affecting the respiratory tract, skin, and urinary system. Market growth is primarily driven by the drug's established clinical safety and its cost-effectiveness as a generic therapeutic, ensuring high prescription volumes across both pediatric and geriatric populations. Furthermore, the increasing global prevalence of infectious diseases consistently fuels demand for this vital antibiotic, despite the emergence of newer antimicrobial classes.However, the market faces significant challenges concerning supply chain stability and manufacturing consistency, which frequently lead to product shortages. These logistical difficulties are often worsened by the low profit margins associated with generic production, deterring investment in capacity expansion. As reported by the American Society of Health System Pharmacists in April 2025, the United States healthcare sector experienced 270 active drug shortages, underscoring the ongoing manufacturing vulnerabilities that threaten the availability of crucial anti-infective agents like Cephalexin.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 389.03 Million
Market Size 2031USD 511.58 Million
CAGR 2026-20314.67%
Fastest Growing SegmentUrinary Tract Infection
Largest MarketNorth America

Market Driver

The escalating incidence of bacterial infectious diseases, particularly respiratory tract infections, fundamentally underpins the commercial demand for Cephalexin. As a first-line therapeutic with a well-documented safety profile, this antibiotic remains indispensable in combating common community-acquired pathogens. This dependency is further highlighted by epidemiological trends indicating a rise in infection rates; for instance, the Centers for Disease Control and Prevention (CDC) reported in its July 2024 'Antimicrobial Resistance Threats in the United States, 2021-2022' report that hospital-onset infections increased by 20% compared to pre-pandemic levels, reinforcing the need for accessible antibacterial treatments.Simultaneously, the expanding global geriatric population acts as a powerful demographic catalyst, significantly increasing prescription volumes due to the heightened susceptibility of older adults to conditions like urinary tract infections. This aging demographic requires consistent access to well-tolerated medications such as Cephalexin, which provides an optimal balance of efficacy and renal safety. According to the UN Department of Economic and Social Affairs in October 2024, the global population aged 60 and above reached 1.2 billion in 2024, creating a substantial patient base. This demographic pressure strengthens the consumption of established generic formulations, with Teva Pharmaceutical Industries reporting a 30% revenue increase in its U.S. generics business during the third quarter of 2024, showcasing the robust momentum for essential off-patent antibiotics.

Market Challenge

The Global Cephalexin Market encounters a significant obstacle in the form of supply chain instability and manufacturing inconsistencies, directly impeding its potential for expansion. As a generic antibiotic characterized by low profit margins, Cephalexin offers limited financial incentives for manufacturers to invest in redundant production capacity or to modernize aging facilities. This economic reality has fostered a fragile ecosystem where production is often concentrated among a few suppliers, making the market highly susceptible to disruptions from quality control failures or raw material shortages. When these logistical bottlenecks occur, the inability to meet consistent clinical demand results in considerable revenue loss and stagnation in consumption volumes.The repercussions of these manufacturing vulnerabilities are particularly acute within the anti-infective segment, disproportionately impacting the availability of essential treatments. The European Association of Hospital Pharmacists reported in November 2025 that 63% of surveyed pharmacists identified antimicrobial agents as the therapeutic class most frequently affected by supply shortages. This high prevalence of stockouts compels healthcare systems to ration existing inventory, thereby effectively placing a ceiling on the market's growth potential and creating a volatile commercial environment that discourages long-term industrial commitment to Cephalexin production.

Market Trends

Manufacturers are increasingly transitioning from traditional chemical synthesis methods to enzymatic processes for producing Cephalexin Active Pharmaceutical Ingredients (APIs). This "green chemistry" approach significantly reduces solvent waste, lowers energy consumption, and yields higher purity products, aligning with global sustainability objectives and stringent environmental regulations. The adoption of enzymatic platforms allows companies to replace complex chemical steps with more efficient biocatalytic routes, thereby substantially diminishing the environmental footprint of beta-lactam antibiotic production while simultaneously optimizing operational efficiency. For instance, Centrient Pharmaceuticals' June 2025 ESG Report highlighted an 8% reduction in Scope 1 and 2 greenhouse gas emissions in 2024 compared to its baseline, demonstrating the tangible sustainability benefits derived from modernizing pharmaceutical manufacturing infrastructure.Beyond its standard human applications, the market is observing a notable rise in specialized veterinary formulations of Cephalexin, specifically designed for companion animals and livestock. This emerging trend includes the development of palatable chewable tablets and long-acting injectables, which aim to treat bacterial infections in pets more effectively, distinguishing this segment from general human generic usage. This targeted focus on animal health is driven by increased pet ownership and the growing willingness of owners to invest in premium medical treatments for conditions like dermatological and urinary tract infections, thereby creating a lucrative niche for manufacturers. Zoetis's February 2025 report on its Fourth Quarter and Full Year 2024 Results, indicating a 7% increase in companion animal product sales in the United States during the fourth quarter of 2024, further reflects the growing financial viability of the veterinary therapeutics sector.

Key Market Players

  • Lupin Limited
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Mylan N.V.
  • Alkem Laboratories Ltd.

Report Scope

In this report, the Global Cephalexin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cephalexin Market, By Sales Channel

  • Direct
  • Indirect

Cephalexin Market, By End Use

  • Urinary Tract Infection
  • Respiratory Infection
  • Otitis Media
  • Bone Infection
  • Others

Cephalexin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cephalexin Market.

Available Customizations:

Global Cephalexin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cephalexin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Urinary Tract Infection, Respiratory Infection, Otitis Media, Bone Infection, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cephalexin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cephalexin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Cephalexin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Cephalexin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Cephalexin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cephalexin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Cephalexin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Cephalexin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Cephalexin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Cephalexin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Cephalexin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cephalexin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Cephalexin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Cephalexin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Cephalexin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Cephalexin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Cephalexin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cephalexin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Cephalexin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Cephalexin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Cephalexin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cephalexin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Cephalexin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Cephalexin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cephalexin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Lupin Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Teva Pharmaceutical Industries Ltd.
  • 15.3. Aurobindo Pharma Limited
  • 15.4. Sandoz International GmbH
  • 15.5. Sun Pharmaceutical Industries Ltd.
  • 15.6. Hikma Pharmaceuticals PLC
  • 15.7. Cipla Limited
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Mylan N.V.
  • 15.10. Alkem Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer